Healthy Clinical Trial
Official title:
Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands
NCT number | NCT04885322 |
Other study ID # | 1344169-8 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 14, 2021 |
Est. completion date | June 30, 2024 |
The purpose of this study is to better understand the neural correlates of higher-order cognition, both in the healthy brain and in schizophrenia, and to determine how these mechanisms are modulated by transcranial direct current stimulation (tDCS) at frontal and occipital scalp sites. Testing the effects of tDCS at these scalp sites on cognitive task performance will help us understand the roles of the brain regions corresponding to these sites during higher-order cognitive processing (language comprehension, cognitive control, and related attention and memory processes). Behavioral and electrophysiological (EEG) measures will be used to assess cognitive performance. Our overarching hypothesis is that stimulating prefrontal circuits with tDCS can improve cognitive control performance, and ultimately performance on a range of cognitive tasks, as compared to stimulating a different cortical region (occipital cortex) or using sham stimulation. This study is solely intended as basic research in order to understand brain function in healthy individuals and individuals with schizophrenia. This study is not intended to diagnose, cure or treat schizophrenia or any other disease.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - between ages of 18 and 50 - ability to sufficiently speak and understand English so as to be able to understand and complete cognitive tasks - ability to give valid informed consent Exclusion Criteria: - no history of head trauma - no current or previous history of treatment with psychotropic medication - corrected vision 20/30 or better - tDCS/MRI contraindications, including: pregnancy, ferrous metal in any part of the body, serious medical conditions, claustrophobia, metallic implants, skin damage, conditions such as eczema at electrode sites, cranial pathologies |
Country | Name | City | State |
---|---|---|---|
United States | Imaging Research Center | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Behavioral Cognitive Control Measures on the Stroop Task | Incongruent versus Congruent difference in error rate and reaction time | Through study completion, an average of 1 month | |
Primary | EEG Cognitive Control Measures on the Stroop Task | response-locked power in the theta frequency band (4-7 Hz) | Through study completion, an average of 1 month | |
Primary | Behavioral Attention Lapse Measures on the Stroop Task | Error Rate on Incorrect Congruent trials (Full Lapses) and Slow-but-Correct Congruent trials (Partial Lapses) | Through study completion, an average of 1 month | |
Primary | EEG Attention Lapse Measures on the Stroop Task EEG Attention Lapse Measures on the Stroop Task | Pre-trial power in the alpha frequency band (8-12 Hz) | Through study completion, an average of 1 month | |
Primary | Behavioral Cognitive Control Measures on the Change Detection Task Behavioral Cognitive Control Measures on the Change Detection Task | WM storage capacity (k-max) | Through study completion, an average of 1 month | |
Primary | EEG Cognitive Control Measures on the Change Detection Task | delay period power in the theta frequency band (4-7 Hz) | Through study completion, an average of 1 month | |
Primary | Behavioral Attention Lapse Measures on the Change Detection Task | Attention factor (a); Guess factor (g) | Through study completion, an average of 1 month | |
Primary | EEG Attention Lapse Measures on the Change Detection Task | Pre-trial power in the alpha frequency band (8-12 Hz) | Through study completion, an average of 1 month | |
Primary | Delivered tDCS Dose to PFC | Estimated electric field in PFC region of interest | Through study completion, an average of 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |